Interviews

Interviews

Are DCTs truly more sustainable?

During the pandemic, sponsors and biotechs started running decentralised clinical trials (DCTs) to keep research going when patients had less…

Interviews

Saving shelved ultra-rare therapies through unorthodox funding

Interviews

Podcast: How will biotech and biopharma manage with more funding cuts?

Interviews

Podcast: USAID – the impact of funding termination on clinical research

Interviews

USAID: sponsors, agencies and foundations may have to fill funding gap

Interviews

FDA protocol deviation guidance could go further

Interviews

How biotechs can recover VAT on EU-based clinical trials

Interviews

Radiopharmaceutical trials face extra complexities due to nuclear red tape

Interviews

Build or buy? Key considerations for in-house manufacturing

Interviews

Clinical trial diversity is a balancing act of time, quality, and money

Interviews

How can (A)I help? AI chatbot to help understand the world of AI regulation

Interviews

Sponsors must take on FDA’s diversity guidance to improve community trust

Interviews

Advancing quality control measures vital for cell and gene therapy development

Interviews

Mendel.ai software aims to save nurses time in pre-screening

Interviews

NHS investment critical to drive cell and gene therapy research

Interviews

How patient advocacy can lead to more successful and meaningful clinical trials

Interviews

EU-X-CT project to clarify cross-border trial access in Europe

Interviews

Q&A: Reinventing the 6MWT with wearable sensors

Interviews

Q&A: Decentralising cryopreservation to improve cell and gene therapy trial logistics

Interviews

Q&A: Dr Christina Yap talks about SPIRIT and CONSORT guidance

Interviews

External controls can augment low populations in rare disease trials

Phalguni Deswal

Interviews

Q&A: Data misuse and trial reporting

Interviews

Q&A: Pharma’s trial diversity goals may not answer health equity problems

Urtė Fultinavičiūtė

Interviews

Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’

Interviews

Q&A: Importance of human touch in patient experience and clinical trial participation

Urtė Fultinavičiūtė

Interviews

‘Migrant-led start-ups do better’: interview with the founder of One Way Ventures

Sebastian Shehadi

Interviews

Q&A: Democratisation and inclusion of patient’s insights in cardiovascular clinical trials

Urtė Fultinavičiūtė

Interviews

Angola’s economic rebound and the impact of the ZEE free-trade zone

Sebastian Shehadi

Interviews

Q&A: Improving paediatric clinical trials with the language of play

Urtė Fultinavičiūtė

Interviews

‘Pejorative politics are the problem, not migrants’: CEO of Fladgate Partnership Adrian Bridge

Sebastian Shehadi

Interviews

Q&A: Ethics of ultra-rare disease drug development and expanded access

Interviews

Better pay for clinical trial participants: in conversation with Gunnar Esiason

Urtė Fultinavičiūtė

Healthcare

Ukraine looks to a future as a hub for medical tourism

Comment

Palestine Action: The sabotage experts turning heads across the business world

Sebastian Shehadi

Sign up to the newsletter: In Brief

Your corporate email address *

First name *

Last name *

Company name *

Job title *

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close